Cellular immune response evaluation of cutaneous leishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis antigenic fractions before and after clinical cure  by Brelaz-de-Castro, Maria Carolina Accioly et al.
Cellular Immunology 279 (2012) 180–186Contents lists available at SciVerse ScienceDirect
Cellular Immunology
journal homepage: www.elsevier .com/ locate/yc immCellular immune response evaluation of cutaneous leishmaniasis patients cells
stimulated with Leishmania (Viannia) braziliensis antigenic fractions before and
after clinical cure
Maria Carolina Accioly Brelaz-de-Castro ⇑, Amanda Ferreira de Almeida, Andresa Pereira de Oliveira,
Marina de Assis-Souza, Lucas Ferreira da Rocha, Valéria Rêgo Alves Pereira
Departamento de Imunologia, Centro de Pesquisas Aggeu Magalhães (CPqAM/FIOCRUZ), Recife, PE, Brazil
a r t i c l e i n f oArticle history:
Received 14 May 2012
Accepted 6 November 2012
Available online 29 November 2012
Keywords:
American cutaneous leishmaniasis
Immune response
T lymphocyte
Antigen
Flow cytometry
Cytokines0008-8749  2012 Elsevier Inc. Open access under the El
http://dx.doi.org/10.1016/j.cellimm.2012.11.006
⇑ Corresponding author. Address: Departamento
Pesquisa Aggeu Magalhães/FIOCRUZ, Av., Professo
Universitária, Campus da UFPE, 50670-420 Recife,
21012640.
E-mail address: carolina.brelaz@gmail.com (M.C.Aa b s t r a c t
American cutaneous leishmaniasis (ACL) is a disease where susceptibility or resistance is dependent on T
cell response. This is characterized by an increased in CD4+ T cells, capable of inducing opposite disease
proﬁles, and CD8+ T cells, that are related to immuno protection. We characterized T lymphocytes from
patients before and after treatment, patients that spontaneously healed and controls, also evaluating
their production of IL-10, IL-4, TNF-a and IFN-c, after stimulation with soluble/insoluble antigenic frac-
tions of Leishmania (Viannia) braziliensis. We observed the production of suppressive cytokines in the
early phase of leishmaniasis with signiﬁcant presence CD4+ T cells, suggesting their connection with dis-
ease progression. After healing, the immune pattern observed was a type 1 response, what seems to be
associated with cure and/or protection in the ACL. The results also showed that both fractions induced a
speciﬁc immune response, contributing to the search for relevant antigens in this disease.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Leishmaniasis is considered an emerging and re-emergent dis-
ease, with an increase in its incidence in the last decades [1]. It
has a global estimated prevalence of 12 million cases, with an esti-
mative of 1.5–2 million new cases each year. At the present mo-
ment leishmaniasis occurs in 88 countries throughout Europe,
Africa, Asia and America, and 350 million people are at risk of con-
tracting the disease [2,3].
The American cutaneous leishmaniasis (ACL) is caused by dif-
ferent species of the genus Leishmania, and Leishmania (Viannia)
braziliensis is the prevalent etiologic agent in Latin America, being
also the prevailing agent in the Northeast region of Brazil and in
the state of Pernambuco [4,5]. The clinical manifestations are
broad and are determined by the species of leishmania, vector vir-
ulence factors and host immune response [3,6]. The pathogenesis
is related to the interactions between the host innate and adaptive
immune system, as well as the nutritional status and genetic fac-
tors. The disease may vary from asymptomatic forms to cutaneous
and mucocutaneous ones [1,3,6].sevier OA license. 
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. Brelaz-de-Castro).In all ACL clinical forms, T lymphocytes are critical for cure and
generation of a protective immune response, also being responsi-
ble for the disease persistence and pathology [7–9]. CD4+ and
CD8+ T cells act producing biologically relevant cytokines for the
activation of monocytes and macrophage. In human leishmaniasis,
the type 1 immune response, with the production of IFN-c, TNF-a
and IL-12, has been associated with the infection control, by mac-
rophage activation and parasite destruction [1,3]. On the other
hand, cytokines like IL-4, IL-10 and TGF-b, considered of type 2,
favor parasite multiplication, inhibiting NO production by IFN-c
activated macrophages [6,7,10]. These cytokines are also able to in-
hibit T cell differentiation into a type 1 proﬁle and the subsequent
production of IFN-c and TNF-a [11]. Therefore, the quality of the
immune response can inﬂuence disease susceptibility and develop-
ment, with speciﬁc activation of T cells (especially multifunctional
T cells) contributing to it [12]. However, even though there are
studies that helped to clarify the immune mechanisms of disease
development and pathology, no clear data is available about what
immune response is necessary to control the disease and what is
the difference between patients that develop the disease and
achieve clinical cure (with or without treatment).
We examined in this study the CD4+ and CD8+ balance ex vivo
and in vivo, and also the intracellular cytokine proﬁle in patients’
cells after stimulation with the soluble and insoluble L. (V.) brazili-
ensis antigenic fractions. The differences in the immune response
and proﬁle of patients before and after treatment, and also of
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gated together with the capacity of our antigens to elicit it, helping
in the development of future vaccines and immunotherapies.2. Methods
2.1. Study group
The patients of the present study were from different endemic
municipalities of Pernambuco, Brazil. Seventeen patients were
selected before treatment (BT), with a disease evolution around
1.6 months; 11 of them returned 6 months after treatment (PT)
and 5 were patients that spontaneously healed (SH). The selection
of these individuals was based on criteria such as: being more than
12 years old, having conﬁrmed diagnosis by the CPqAM/FIOCRUZ
Leishmaniasis Referee Center, being active lesion carriers when
BT patients or having re-epithelized characteristic lesions (scars)
when PT and SH patients. The test results of the study group are
summarized in Table 1.
Patients selected before treatment were submitted to blood col-
lection prior to chemotherapy treatment with Glucantime (Sano-
ﬁ-Aventis, Suzano, SP, Brazil). Patients that returned after
treatment and that spontaneously healed had their blood collected
after cicatrization of their lesions. Ten healthy individuals (CT) rep-
resented the control group from non endemic areas and without
previous ACL infection. All of them signed the ‘‘Term of Free and
Informed Consent’’. The CPqAM/FIOCRUZ Research Ethics Commit-
tee, Recife, Brazil approved the experimental protocols.2.2. Leishmania antigenic fractions
Promastigote forms of L. (V.) braziliensis (MHOM/BR/75/M2903),
cultured in vitro, were expanded in Schneider’s medium (Sigma, St.
Louis, MO) supplemented with 10% of fetal calf serum (Cultilab,Table 1
Test results of the study group and patient status.
Patient Study group
MSTa
(mm)
Direct
microscopy
IFIb PCRc Number of
Ampsd
Patients
status
1 10 + + N/D 1 SH
2 10 N/D  N/D 0 SH
3 10 N/D  N/D 0 SH
4 8  + + 40 BT, PT
5 10 + + N/D 100 BT, PT
6 10  + N/D 40 BT, PT
7 N/D  + N/D 40 BT
8 8  N/
D
N/D 60 BT, PT
9 8  + N/D 20 BT, PT
10 N/D  + + 24 BT, PT
11 10  + + 40 BT, PT
12 10  + + 100 BT
13 11  + N/D N/I BT
14 9  + N/D 0 SH
15 14  + + 40 BT
16 10   N/D 0 BT, SH
17 12  + + 80 BT
18 16   + 40 BT, PT
19 14 +  + 40 BT, PT
20 9 +  + 40 BT, PT
21 14 + + + 40 BT, PT
+: positive; : negative; NI: not informed; N/D: not done; BT: before treatment; PT:
after treatment; SH: spontaneously healed.
a Montenegro skin test.
b Indirect immunoﬂuorescence.
c Polymerase chain reaction.
d Number of Ampoules of Glucantime used.Campinas, SP, Brazil) and 1% of antibiotics (100 UI/ml penicillin
and 100 lg/ml streptomycin; Sigma, St. Louis, MO) until they
reached the exponential phase. Afterwards, they were sedimented
by centrifugation at 800g for 15 min at 4 C and three times
washed with phosphate-buffered saline (PBS; pH 7.2). Proteases
inhibitors such as 0.1 mMmethyl-phenyl-ﬂuoride and 2 mM ethyl-
enediaminetetraacetic acid (Sigma, St. Louis, MO), pepstatin A
0.001 M (Sigma, St. Louis, MO), were added right after ultrasoni-
cate (100 w/10 cycle/30 s with 2 pulses/s). The parasitic suspen-
sion was centrifuged at 10,000g for 10 min at 4 C. The
resultant supernatant was removed and submitted to a new centri-
fugation at 100,000g for 1 h at the same temperature. The resul-
tant supernatant was the soluble antigenic fraction (SOL), while
the sediment was the insoluble antigenic fraction (INS). Both were
submitted to protein determination according to Brito et al. [13].
The antigens were stored at 20 C until use.
2.3. Electrophoretic proﬁle of soluble and insoluble antigens of L. (V.)
braziliensis
The protein proﬁle of the soluble and insoluble antigens of L.
(V.) braziliensis were determined by a SDS (sodium dodecyl sul-
fate)–polyacrylamide gel electrophoresis. They presented proteins
whose molecular weights varied between approximately 66 and
16 kDa compared to the standard molecular weight (Sigma, St.
Louis, MO) (Fig. 1).
2.4. Obtaining the PBMC
Forty milliliters of peripheral blood in heparinized tube were
collected, diluted in a proportion of 2:1 in PBS pH 7.2 and then
added to a Ficoll-Hypaque (Amersham Biosciences, Uppsala, Swe-
den) gradient. After centrifugation at 400g for 30 min at 20 C a
peripheral blood mononucleated cells (PBMCs) ring was obtained.
The cells were washed twice with PBS pH 7.2 and submitted to
centrifugation (300g for 15 min at 20 C). PBMCs were resus-
pended with RPMI 1640 medium (Cultilab, Campinas, SP, Brazil)
supplemented with 10% of fetal calf serum (Cultilab, Campinas,Fig. 1. SDS–PAGE of soluble proteins (1 and 2) and insoluble (3 and 4) of L. (V.)
braziliensis. In wells 1 and 3 were deposited 10 lm of antigen, while 15 mg of
antigen were placed into wells 2 and 4. M = molecular weight markers in kDa (66 –
bovine serum albumin; 45 – ovalbumin; 36 – carbonic anhydrase; 29 – glyceral-
dehyde 3-phosphate dehydrogenase; 24 – trypsinogen, 20.1 – trypsin inhibitor and
14.2 – a-lactalbumin).
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streptomycin; Sigma, St. Louis, MO) and then counted in a Neu-
bauer chamber using Trypan blue (Sigma, St. Louis, MO). The cells
where then adjusted to a concentration of 4  106 per tube/ml.
2.5. Cell culture and ﬂow cytometry
PBMCs (4  106 per tube/ml) were incubated with Leishmania
soluble (SOL, 1.25 lg/ml) and insoluble (INS, 2.25 lg/ml) antigenic
fractions (37 C/5% CO2), for 48 h, by means of previous standardi-
zation. Brefeldin A (10 lg/ml) (Sigma, St. Louis, MO) was added to
all tubes 4 h prior to the end of the incubation period. After the
incubation time, ethylene-diamine-tetra-acetic acid (EDTA,
20 mM) (Sigma, St. Louis, MO) was added to the culture and then
incubated for 10 min. The cells where then washed with PBS with
0.5% bovine serum albumin (Sigma, St. Louis, MO) and 0.1% sodium
azide (Sigma, St. Louis, MO), a solution called PBS-W, centrifuged
(370g, 7 min, RT) and transferred to polystyrene tubes. The tubes
contained monoclonal antibodies anti-CD4 or anti-CD8, both la-
beled with ﬂuorescein isothiocyanate (FITC) (BD Bioscience, San
Jose, CA), and the cells were incubated for 30 min at RT. Afterward
the cells were ﬁxed with 1% paraformaldehyde in PBS, washed by
centrifugation with PBS-W (400g, 5 min) and permeabilized with
PBS plus 0.5% of saponin. Subsequently, the cells were washed with
PBS-W by centrifugation (400g, 5 min) and then incubated with
cytokine-speciﬁc antibodies against IFN-c, TNF-a, IL-10 (Miltenyi
Biotec, Bergisch Gladbach, Germany) and IL-4 (BD Bioscience, San
Jose, CA), all labeled with phycoerythrin (PE), for 30 min, RT. After
this time, they were washed by centrifugation with PBS-W (400g,
5 min) and resuspended with 1% paraformaldehyde in PBS. The
samples were then analyzed (20,000 events/tube) through ﬂow
cytometry (FACSCalibur-BD, San Jose, CA) using the software CELL-
QuestPro™ (BD Bioscience, San Jose, CA) for acquisition and analy-
sis of data.
2.6. Peripheral blood immunophenotypic analysis
To determine the percentage of CD4+ and CD8+ T cells, 5 ml of
peripheral blood were collected in tubes containing EDTA. Subse-
quently 100 ll blood aliquots were transferred to cytometry tubes
containing monoclonal antibodies speciﬁc for the cell surface
markers anti-CD4 or anti-CD8 conjugated with FITC (BD Biosci-
ence, San Jose, CA) and incubated for 30 min. Afterwards, the sam-
ples were submitted to erythrocytes lysis, followed by 2 washes
and centrifugations (7 min, 300g), with posterior resuspension
in 400 ll of a 1% paraformaldehyde PBS solution. The cells immu-
nophenotypic and morphometric parameters were determined by
ﬂow cytometry (FACSCalibur-BD, San Jose, CA) using the software
CELLQuestPro™ (BD Bioscience, San Jose, CA) for acquisition and
analysis of data (50,000 events/tube).
2.7. Analysis
The analyses were done ﬁrst delimitating the lymphocytic re-
gion in a Forward Scatter (FSC) versus Side Scatter (SSC) graph.
Based on this region the ﬂuorescence graphs (FL1  FL2) were con-
structed, delimitating the quadrants for analyses. The quadrant
limits were based on the negative population and previous anti-
bodies titration. The values considered for the ﬂuorescence analy-
sis were the percentage of the quadrant region for each quadrant.
The statistical analyses were performed through SPSS 8.0 and
GraphPad Prism 5.1, using nonparametric tests. For intragroup
comparative analysis, the Kruskal–Wallis test was used and to de-
tect differences between groups, the Mann–Whitney U-test, based
on the two-tailed p value. The results were analyzed considering
the value of p < 0.05 (statistically signiﬁcant).3. Results
3.1. CD4+ and CD8+ T lymphocytes percentage in PBMC cultures after
stimulation with Leishmania soluble and insoluble antigens: distinct
patterns
In a phenotypic analysis of responding T cells after culture, we
could observe that patients cells before and after treatment pre-
sented a superior and signiﬁcant percentage of CD4+ T cells when
compared to the control group (BT  CT: p = 0.018 SOL/p = 0.040
INS; PT  CT: p = 0.037 SOL/p = 0.022 INS) and also superior when
compared to the spontaneously healed group. The percentage of
CD4+ T cells from patients that spontaneously healed was superior
to the one of the control group, but without statistical signiﬁcance
(Fig. 2).
The percentage of the CD8+ T cells in cultures, on the other
hand, was inferior to controls in patients before treatment, but in-
creased substantially and signiﬁcantly after treatment (PT  CT:
p = 0.033 SOL/p = 0.025 INS). The percentage of CD8+ T cells in pa-
tients that spontaneously healed was also higher and signiﬁcantly
different when compared to patients before treatment (SH  BT:
p = 0.023 SOL/p = 0.021 INS). When the insoluble leishmania anti-
genic fraction was used the percentage of T CD8+ cells from SH
were also signiﬁcantly different when compared to controls
(SH  CT: p = 0.028 INS) (Fig. 2).3.2. T CD4+ and T CD8+ comparison in ex vivo and culture assays
demonstrated a lower CD4/CD8 ratio in PT and SH patients
In order to demonstrate the CD4+ and CD8+ T cellular proﬁle
during an immunological response, we performed a comparison
between the percentage of these lymphocytes in the peripheral
blood of patients and controls in an ex vivo context and after PBMC
culture with the soluble (SOL) and insoluble (INS) antigenic frac-
tions of L. (V.) braziliensis.
Patients showed no signiﬁcant differences when comparing the
percentage of CD4+ T lymphocytes in the ex vivo assays and in cul-
tures with the antigens. Regarding CD8+ T lymphocytes it is inter-
esting to note that SH and PT patients, presented higher levels of
these cells after stimulation with the SOL and INS antigens. This
difference was statistically signiﬁcant when comparing the per-
centage of CD8+ T cells in the ex vivo situation with the CD8+ T cells
after stimulation with the soluble and insoluble antigenic fraction
(ex vivo  SOL p = 0.006; ex vivo  INS p = 0.001) (Fig. 2).
Comparing the CD4/CD8 ratio in the ex vivo assays and in the
PBMC cultures, we found a variation in the values presented by
the groups. Patients BT, PT and SH in the ex vivo assays, as well
BT cultures, showed a CD4/CD8 ratio >2, while SH patients in the
ex vivo assays and the PT and SH after antigenic stimulation with
the antigenic fractions showed a ratio <2 (Table 2).3.3. Leishmania antigens induced different cytokine proﬁles, with a
predominant Th2 proﬁle in the beginning of infection and a Th1 one
after therapy
The cellular source and frequency of cytokine-producing cells
induced by antigenic fractions of L. (V.) braziliensis, were deter-
mined after culture. When the soluble and insoluble antigenic frac-
tions were used, different proﬁles were observed. After stimulation
with the antigens, CD8+ T cells were the main responsible for the
production of IFN-c and TNF-a, the latter only in BT patients.
CD4+ T cells were mainly producers of IL-10 and IL-4, besides
TNF-a in PT and SH patients (Figs. 3 and 4).
The soluble antigen fraction stimulated CD4+ T to produce IL-10
(BT  CT p < 0.0001) and IL-4 (BT  CT p = 0.030), and CD8+ T cells
Fig. 2. CD4+ and CD8+ T cells percentage comparison in cultures and ex vivo assays. The differences were considered signiﬁcant at p less than 0.05 and are represented by the
symbols: a = Intragroup difference (ex vivo  SOL  INS);  = difference between BT  CT; d = difference between PT  CT;  = difference between SH  BT; H = difference
between SH  CT. BT = before treatment/PT = after treatment/SH = spontaneously healed/CT = controls..
Table 2
CD4+ T/CD8+ T cell ratio ex vivo and in cultures stimulated with leishmania soluble
and insoluble antigenic fractions.
CD4+/CD8+ ratio Ex vivo Soluble antigen Insoluble antigen
BT 2.39 2.6 2.38
PT 2.29 1.4 1.65
SH 1.69 1.3 1.12
CT 2.48 1.71 1.74
M.C.A. Brelaz-de-Castro et al. / Cellular Immunology 279 (2012) 180–186 183to produce TNF-a, IL-4 and IL-10 (BT  CT p = 0.016) before treat-
ment. After treatment there was a change in this proﬁle, with a
decreased in the production of IL-4 and IL-10 (BT  PT p = 0.003)
and signiﬁcant increase in the production of IFN-c (PT  BT
p = 0.023) and TNF-a (PT  BT p = 0.0002/PT  CT p = 0.005) by
CD4+ T cells. However, patients still had a signiﬁcant production
of IL-10 (PT  CT p = 0.005) by CD4+ T cells. CD8+ T had a similar
proﬁle, with a decrease in IL-4 and IL-10 production (BT  PT
p = 0.008), and a signiﬁcant increase in TNF-a (PT  BT p = 0.014)
and IFN-c (PT  BT p = 0.020) by CD4+ T cells. SH Patients showed
a higher production of TNF-a, IFN-c and IL-4 by CD4+ T cells and
TNF-a and IFN-c (SH  BT, p = 0.046) by CD8+ T cells. When consid-
ering the production of IL-10 by SH group, signiﬁcant difference
was seen in the production of CD4+ T cells (BT  SH p = 0.037/
SH  CT p = 0.019) (Fig. 3A and B).
The insoluble antigenic fraction stimulated a signiﬁcant pro-
duction of IL-10 (BT  CT p = 0.005) and IL-4 (BT  CT p = 0.028)
by CD4+ T cells before treatment. The CD8+ T cells produced a rel-
evant amount of IL-10 (p = 0.004) when comparing BT  CT. After
treatment, an increase in the production of IFN-c and TNF-a was
seen, being the last one signiﬁcant between patients PTBT by
CD4+ (p = 0.003) and CD8+ (p = 0.006) T cells. When considering
CD8+ T cells the production of IL-10 and IL-4 before and after
treatment was similar. Signiﬁcant difference was seen in the per-
centage of IL-10 (p = 0.020) between the PT  CT by CD4+ T cells.
The SH group presented a higher production of TNF-a (T CD4+,
SH  CT p = 0.002) and a lower production of IL-10 when com-
pared to the one of CD4+ (p = 0.008) and CD8+ (p = 0.001) T cells
from BT  SH and with CD8+ T cells of PT  SH groups (Fig. 3A
and B).4. Discussion
Human leishmaniasis infection resolution is dependent pri-
marily on the events of T cell subtypes and cytokine production
proﬁle [9,14]. However, the relationship of these mechanisms is
still not well-established, especially in human L. (V.) braziliensis
infections. In the present study we characterized patients before
(BT) and after treatment (PT) and those that spontaneously
healed (SH) immunophenotypically. Ex vivo and culture assays
were performed, and we analyzed the cytokines produced in
these cultures under in vitro stimulation with soluble or insoluble
antigenic fractions of L. (V.) braziliensis—thereby characterizing
and describing the speciﬁc immune response proﬁle induced by
these fractions.
PBMC cultures revealed a decrease in the CD4+/CD8+ T cells
ratio in patients BT compared to those PT. The SH patients had
the lowest CD4+/CD8+ T cells ratio, with a proportion of CD4+ T cells
comparable to CT and a proportion of CD8+ T cells higher than
patients PT and signiﬁcant when compared with patients BT.
CD4+ T cells are capable of inducing opposite disease developing
proﬁles, depending on their cytokine production. Our results
suggest their involvement in both the pathology and in its cure,
as it has been observed by other groups [15,16]. The CD8+ T cells
have been involved in the control of ACL infection, and several
authors have reported their increase in healed patients, suggesting
its role by modulating the activity of CD4+ T cells, by direct
cytolytic effect of macrophages infected, or even with regulatory
effects [9,15,17–20]. Our results conﬁrm that a balance between
the proportion of CD4+ and CD8+ T cells is important for lesion
healing, a hypothesis also reinforced by others [15,18,20].
It is important to highlight that the treatment with antimonials
promotes a change in the host response to the parasite, either by
its direct destruction or by increasing the capacity of the host to
combat it. Nevertheless, studies byDa-Cruz et al. [15] demonstrated
that the observed changes in the percentage of CD4+ and CD8+ T cells
was a Leishmania speciﬁc response. In our work, the ex vivo study of
CD4+ and CD8+ T cells of patients showed no signiﬁcant difference,
which was seen only after antigen stimulation—what suggests a
speciﬁc stimulation by our antigen. The values observed ex vivo
are, however, in agreement with the averages obtained by Autissier
et al. [21] and Faria et al. [22], suggesting that deleterious changes
Fig. 3. Cytokine expression by (A) CD4+ and (B) CD8+ T cells after in vitro stimulation with: Leishmania soluble antigenic fraction (1.25 lg/ml) and Leishmania insoluble
(2.25 lg/ml) antigenic fraction. The results are expressed as mean values ± SEM. The differences were considered signiﬁcant at p less than 0.05 and are represented by the
symbols:  = difference between PT  BT; j = difference between BT  SH; H = difference between SH  CT; d = difference between PT  CT; h = difference between
PT  SH;  = difference between SH  BT;  = difference between BT  CT; s = difference between BT  PT. BT = before treatment/PT = after treatment/SH = spontaneously
healed/CT = controls.
Fig. 4. Representative FACS dot plots of cytokine expression by (A) CD4+ and (B) CD8+ T cells.
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the study by Botelho et al. [23].
Studies have shown that antigens from the promastigote forms
of L. (V.) braziliensis, intact or sonicated, were able to induce differ-ent levels of cellular immune response [4–6,12,18–20,25,26,31]
and noted that the search for antigenic molecules is relevant for
the identiﬁcation of new subunit vaccine candidates and targets
for immunotherapy. This reinforces the importance of our study
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fractions of L. (V.) braziliensis.
This study, comparing the evolution of patients BT, PT and SH
observed a signiﬁcantly production of IL-10 and IL-4 by CD4+ T
lymphocytes in BT patients. An inversion of this situation, with in-
creased production of IFN-c and TNF-a, was seen after treatment
with Glucantime, where IFN-c was mainly produced by CD8+ T
cells and TNF-a by CD4+ T cells. The SH patients exhibit a predom-
inance of type 1 proﬁle with IFN-c and TNF-a, however, still with
production of Th2 cytokines. The PT patients showed similar re-
sults to the ones of SH, suggesting that this is an immunological
proﬁle associated with healing. In addition to reinforcing the
importance of a type 1 immune response in the evolution for a
healing and immunity from the disease, our work also showed that
the presence of IL-10, an inhibitory cytokine, is essential as a coun-
terbalance and control of an exacerbated immunopathology, a re-
sult also suggested by other groups [11,19].
In studies with L. (V.) braziliensis it was found that in early ACL
(<60 days) it is observed a preferential production of IL-10 and that
there is a low or absent IFN-c production. This pattern then evolves
into a predominantly Th1 cytokine proﬁle, where patients have
IFN-c production and lymphoproliferation [11,27,28]. Our results
and those of other groups suggest that susceptible individuals after
exposure to the parasite develop a type 2 immune response, allow-
ing parasite survival and growth and the development of lesions.
With the progression of the disease, this response changes to type
1 proﬁle, activating macrophages, which leads to the control of
parasite growth and disease progression. Therefore, it is possible
that the development of the disease depends on a temporary im-
mune dysregulation during the early stages of ACL [1,5,11], since
works correlate the participation of IL-10 and IL-4 with the evolu-
tion of ACL [27,29,30].
Most patients with ACL heal after treatment with antimonials,
which indicates a later development of an appropriate and beneﬁ-
cial immune response [7,27,28]. In the present study we saw that
there was a signiﬁcant increase in production of TNF-a and IFN-c
in PT patients. It is interesting to note that SH patients had the
same proﬁle, with the production of TNF-a and IFN-c, even in
the absence of chemotherapy. In endemic L. (V.) braziliensis areas
spontaneously cured patients have been documented, showing this
immune response proﬁle even without treatment [7,24]. This re-
sult reinforces the importance of the type 1 response, and demon-
strates that it is necessary to control the multiplication and
dissemination of Leishmania. Although there is no clinical or labo-
ratory test to predict which patients will respond or fail to treat-
ment with antimonials, it is likely that patients producing high
levels of TNF-a and IFN-c have a better prognosis for cure in infec-
tions with L. (V.) braziliensis.
However, although a type 1 immune response is critical for the
control of leishmaniasis, the loss of an appropriate modulation is
responsible for the immunopathology [28]. In our study IL-10 pro-
duction by CD4+ T lymphocytes in PT patients when stimulated
with both antigenic fractions and by SH patients when stimulated
with the soluble antigenic fraction, was not associated with a low
production of IFN-c and TNF-a. This indicated a coordinated
immunoregulation of T cells that produce protective and poten-
tially pathogenic cytokines, a situation that leads to the resolution
of the ACL infection. Therefore, as evidenced by our PT and SH pa-
tients, a proper balance between the responses that induce a leish-
manicidal activity, those that induce the disease, and those that
maintain the parasite persistence may be the most desired type
of response against infection by L. (V.) braziliensis.
The immune pattern observed in the current study appears to
be associated with the healing and/or protection in ACL, suggesting
the existence of memory T cells and immunoregulatory mecha-
nisms, whose function were triggered by our antigens. Patients’treatment can be beneﬁciated by immunological interventions if
the exact role of T cells subtypes in the disease and resistance
can be clariﬁed [7,12,17,29]. The immune response developed by
patients against the antigens will be useful in determining an ac-
tive disease prognosis and the necessary mechanisms for its evolu-
tion to cure. The observed result may also be an important
parameter for future selection of antigens candidates for vaccine
and prognostic tests, since the development and maintenance of
a protective immune proﬁle is very important and there is not
yet a well deﬁned antigen for the quest. This investigation adds
informations to the search of factors that contribute to the suscep-
tibility and putative protective immunity against human cutane-
ous leishmaniasis in L. (V.) braziliensis infection and provides
additional information on the search for relevant antigens in this
disease.
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